Ultrahypofractionation and Normal Tissue Toxicity

Description

This research is being done to see if proton beam radiation therapy (PBT) results in fewer changes to a participant's heart measured with MRI-imaging than conventional or "photon" radiation therapy (XRT) for participants with non-metastatic left sided breast cancer. The names of the two study groups in this research study are: * Proton Radiation Therapy (PBT) * Conventional or "Photon" Radiation Therapy (XRT)

Conditions

Breast Cancer, Breast Cancer Female, Breast Cancer Stage II, Breast Cancer Stage III, Myocardial Fibrosis

Talk to us

Study Overview

On this page

Study Details

Study overview

This research is being done to see if proton beam radiation therapy (PBT) results in fewer changes to a participant's heart measured with MRI-imaging than conventional or "photon" radiation therapy (XRT) for participants with non-metastatic left sided breast cancer. The names of the two study groups in this research study are: * Proton Radiation Therapy (PBT) * Conventional or "Photon" Radiation Therapy (XRT)

Proton Versus Photon Ultrahypofractionated Radiation Therapy and Its Impact on Normal Tissue

Ultrahypofractionation and Normal Tissue Toxicity

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States, 02215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ≥18 years of age
  • * Non-metastatic Breast Cancer patients who are scheduled to receive conventional left-sided or bilateral breast/chest wall RT inclusive of treatment to the internal mammary lymph nodes (IMNs)
  • * Prior chemotherapy is permitted
  • * Ability to understand and the willingness to sign a written informed consent document
  • * No contraindication to MRI
  • * Patients with right-sided breast cancer or patients with left-sided patients not requiring treatment to the IMNs, but where cardiac anatomy is determined to be unfavorable by the study PI, will be considered eligible.
  • * Person who is pregnant or breastfeeding.
  • * Patients receiving any other investigational agent will not be excluded from study eligibility, unless the patient is already enrolled in an interventional study evaluating cardiac toxicity. No cytotoxic therapy or radiotherapy may be used during radiation therapy.
  • * Contra-indication to gadolinium contrast (e.g., chronic kidney disease)
  • * Contra-indication to radiotherapy (e.g., scleroderma, p53 mutation)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massachusetts General Hospital,

Rachel Jimenez, MD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

2025-09-17